首页> American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons> Avoidance of CNI and steroids using belatacept-Results of the Clinical Trials in Organ Transplantation 16 trial.

Avoidance of CNI and steroids using belatacept-Results of the Clinical Trials in Organ Transplantation 16 trial.

导出 OA

翻译打印收藏纠错

第一作者： Roslyn B,Mannon

第一单位： Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

作者： Roslyn B,Mannon ^[1] ; Brian,Armstrong ^[2] ; Peter G,Stock ^[3] ; Aneesh K,Mehta ^[4] ; Alton B,Farris ^[5] ; Natasha,Watson ^[6] ; Yvonne,Morrison ^[6] ; Minnie,Sarwal ^[3] ; Tara,Sigdel ^[3] ; Nancy,Bridges ^[6] ; Mark,Robien ^[6] ; Kenneth A,Newell ^[5] ; Christian P,Larsen ^[5]

作者单位： Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA. ^[1] Rho Inc, Durham, North Carolina, USA. ^[2] Department of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, California, USA. ^[3] Emory Transplant Center, Emory University School of Medicine, Atlanta, Georgia, USA.;Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. ^[4] Emory Transplant Center, Emory University School of Medicine, Atlanta, Georgia, USA. ^[5] Transplantation Branch, National Institute Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. ^[6]

关键词 clinical research/practice clinical trial costimulation immunosuppressant - fusion proteins and monoclonal antibodies: belatacept immunosuppression/immune modulation kidney transplantation / nephrology rejection: T cell-mediated (TCMR)

医学主题词移植物排斥(Graft Rejection);移植物存活(Graft Survival);免疫抑制剂(Immunosuppressive Agents);肾移植(Kidney Transplantation);器官移植(Organ Transplantation);甾类(Steroids)

DOI 10.1111/ajt.16152

PMID 32558199

发布时间 2023-01-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交